1 July 2026

genedrive plc

("genedrive" or the "Company")

Board change

genedrive plc (AIM: GDR), the point of care pharmacogenetic testing company, today announces that further to the Company's announcement of 26 May 2026 detailing various immediate and proposed board changes, Dr. Ian Gilham, Chairman and a Director of genedrive, has today stepped down from the Board.

The recruitment process for a new independent Non-Executive Chairman as well as two other independent Non-Executive Directors is progressing and further announcements will be made in due course.

As also confirmed in the 26 May 2026 announcement, Chris Yates continues to act as an independent Non-Executive Director pending the appointment of new Non-Executive Board members.

Gino Miele, CEO of genedrive plc, said:

"I would like to thank Ian for his commitment to genedrive and for the invaluable contributions he has made over many years in helping to shape the Company and its mission to transform patient outcomes through rapid pharmacogenetic testing. On behalf of the Board and the entire team at genedrive, both past and present, I wish him every success for the future. We look forward to welcoming our new Non-Executive Chairman and Non-Executive Directors and will update the market in due course."

Subscribe to our news alert service: https://investors.genedrive.com/s/efea03 

About genedrive plc (http://www.genedrive.com).

genedrive plc is a UK-based, commercial-stage pharmacogenetic testing company focused on rapid, point-of-care diagnostic tests to guide safe and effective drug prescription in emergency and acute care settings.

genedrive's proprietary technology platform enables clinicians to prescribe safer and more effective therapies based on a patient's genetic profile, supporting improved outcomes while reducing pressure on healthcare systems, lowering downstream healthcare costs through the prevention of avoidable complications and earlier, more effective intervention

The Company has two CE-IVD approved and NICE-recommended tests in NHS clinical use. The Genedrive® CYP2C19 ID Kit identifies stroke patients who will not respond to the current standard of care, Clopidogrel, used to reduce risk of secondary stroke. The Genedrive® MT-RNR1 ID Kit helps prevent antibiotic-induced hearing loss (AIHL) in newborns, enabling treatment decisions within actionable timeframes at the point of care.

Headquartered in Manchester, genedrive is focused on scaling UK-developed precision diagnostics within routine care and leveraging real-world evidence to support broader international adoption and commercial growth.